DMAAR
Drugs Made In America Acquisition Corp. RightsKey Statistics
About Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC) poised to merge with leading pharmaceutical companies in the United States, focusing on enhancing domestic drug manufacturing capabilities to meet increasing healthcare demands and mitigate supply chain issues. With a seasoned management team, DMAAR is well-positioned to capitalize on growth opportunities within the pharmaceutical sector, aiming to deliver substantial returns to investors while contributing to a more resilient and self-sufficient American healthcare landscape. The company's unique approach aligns with evolving market trends and regulatory shifts, making it an attractive prospect for institutional investors seeking to make a meaningful impact in the pharmaceutical industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.22 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 18.80% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $20.40M |
| Float | $27.90M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting